IDEAYA Biosciences, Inc. (IDYA) Operating Margin
- Operating margin · 12 months: Value -92.66%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -92.66% | Operating income / revenue. Period ending 2026-06-30. $-216.95M ÷ $234.13M × 100 ≈ -92.66% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -216.95M USD | Operating Income (Loss) |
| Revenue | 234.13M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 374.01M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-216.95M | $234.13M | (m) | $374.01M | (m) | -92.66% |
| 2026-03-31 | $-183.47M | (m) | (m) | $339.54M | (m) | (m) |
| 2025-12-31 | $-159.31M | $218.71M | (m) | $314.70M | (m) | -72.84% |
| 2025-09-30 | $-208.88M | $214.83M | (m) | $368.29M | (m) | -97.23% |
| 2025-06-30 | $-384.23M | (m) | (m) | $342.45M | (m) | (m) |
| 2025-03-31 | $-360.35M | (m) | (m) | $322.75M | (m) | (m) |
| 2024-12-31 | $-326.98M | $7.00M | (m) | $294.67M | (m) | -4671.07% |
| 2024-09-30 | $-224.75M | $3.92M | (m) | $193.26M | (m) | -5730.60% |
| 2024-06-30 | $-191.38M | $11.96M | (m) | $169.81M | (m) | -1600.08% |
| 2024-03-31 | $-159.17M | $15.51M | (m) | $144.45M | (m) | -1026.55% |
| 2023-12-31 | $-134.43M | $23.39M | (m) | $129.51M | (m) | -574.85% |
| 2023-09-30 | $-118.95M | $23.48M | (m) | $115.45M | (m) | -506.51% |
| 2023-06-30 | $-84.77M | $45.15M | (m) | $104.12M | (m) | -187.77% |
| 2023-03-31 | $-74.56M | $47.45M | (m) | $97.74M | (m) | -157.13% |
| 2022-12-31 | $-62.50M | $50.93M | (m) | $89.54M | (m) | -122.72% |
| 2022-09-30 | $-54.43M | $49.87M | (m) | $80.93M | (m) | -109.14% |
| 2022-06-30 | $-66.80M | $29.15M | (m) | $74.06M | (m) | -229.18% |
| 2022-03-31 | $-55.35M | $32.05M | (m) | $66.25M | (m) | -172.69% |
| 2021-12-31 | $-50.27M | $27.94M | (m) | $58.16M | (m) | -179.91% |
| 2021-09-30 | $-37.18M | $35.55M | (m) | $54.10M | (m) | -104.58% |
| 2021-06-30 | $-30.46M | $35.54M | (m) | $48.62M | (m) | -85.71% |
| 2021-03-31 | $-32.00M | (m) | (m) | $42.24M | (m) | (m) |
| 2020-12-31 | $-35.34M | $19.54M | (m) | $39.70M | (m) | -180.90% |
| 2020-09-30 | $-41.38M | (m) | (m) | $36.19M | (m) | (m) |
| 2020-06-30 | $-48.01M | (m) | (m) | $35.09M | (m) | (m) |
| 2020-03-31 | $-46.66M | (m) | (m) | $35.35M | (m) | (m) |
| 2019-12-31 | $-44.27M | (m) | (m) | $34.32M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-36.42M | (m) | (m) | $31.75M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-14.44M | (m) | (m) | $12.38M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |